

FucoBalan®

Low Molecular Weight Fucoidan+
High Stability Fucoxanthin

Health Ingredient Verified with
Human Clinical Trial



Product features

Botanical Origin	Laminaria Japonica
Molecular Size	500-1500 Daltons
Water-Soluble Polysaccharides	≥40%
Packaging	2 kg/pack; 20kg/Carton
Safety & Quality Testing	Every lot of production
Shelf Life	3 years

Application

Product form as capsules, tablets, Solid drinks, powder sachets. Suitable for all kinds of health supplement, functional food & nutritional formulation products



Enhancement of Glucose Homeostasis, Lipid Metabolism, and Liver Function

FucoBalan® blends combine the benefits of both Oligo Fucoidan and High Stability Fucoxanthin to provide a safe & bioactive functional ingredients. Water soluble, allowing formulations with other ingredients into health supplements, functional food or beverages.

Fucoidan is a kind of polysaccharide containing sulfated fucose, which is extracted from seaweeds. Hi-Q acquired unique extraction technology from government and improved the technology to produce 500-1500 Daltons molecular weight Fucoidan.

HS Fucoxanthin is a kind a carotenoids which is extracted from seaweeds. Advanced coating technology to maintain high stability and bioactivity of Fucoxanthin in the marine polysaccharide during storage time.

We further focus on scientific researches and human clinical trials to proven safety & functional efficacy; thus with about 10 scientific & medical publication journals accepted by international professional authoritative to prove our scientific data & health claims, and evidences of efficacy scientifically.

Appearance	Yellow brown powder form
Flavor	No odor; Slight seaweed taste
Heat & Stability	100 °C (1 hour) ; 121 °C (30 mins)
Suggest Use & Suitable for	Immune health : 0.5-1.0g/day Diabetes care : 1.5g/day Obesity/Fatty Liver : 3g/day

* Consult with professional dietitian or physician



FucoBalan® Research & Support Evidences

Studies undertaken by Hi-Q research team has investigated the efficacy of our ingredients in a diverse range of indications and clinical settings, including comprehensive in vitro investigations, animal studies and human clinical trials.






Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

A Double-blind, randomized placebo-controlled clinical trial
Taipei Medical University-Wan Fang Medical Hospital Center

- 42 adult patients with Non-alcoholic Fatty Liver Disease (NAFLD), were randomized into the treatment group supplement with 1650mg FucoBalan®, two times daily or control group with placebo.
- Study subjects taking FucoBalan® daily, resulted in significant difference of ALT & CAP reduction, steatosis, HbA1C and adiponectin change in the treatment group, indicating its potential hepatoprotective effect on NAFLD and blood sugar control in diabetes.
- Significant improvements of pancreatic β -cell



	Improvement Rate after Treatment
Terms	3 Month
ALT	85.7%
CAP	57.1%
Stiffness	66.7%
Insulin	47.6%
Insulin resistant	47.6%
Pancreatic β -cell	52.4%



A comprehensive clinical study report will be developed for publication.

†Wu et al., Low-Molecular-Weight Fucoidan and Highly Stability Fucoxanthin decreases ALT in patients with non-alcoholic fatty liver disease (NAFLD). A Double-blind, randomized placebo-controlled clinical trial, Taipei Medical University-Wan Fang Medical Hospital Center. ALL INFORMATION CONTAINED IN THIS BROCHURE IS PROVIDED FOR SCIENTIFIC RESEARCH & PRODUCT DEVELOPMENT PURPOSES. HIGHLIGHTS OF SCIENTIFIC DATA, FIGURE & TABLE INFORMATION ARE PROVEN BY THE RESEARCH STUDIES